Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 229, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2021.114053
Keywords
Multiple myeloma; Small molecular agents; Research overview
Categories
Funding
- National Natural Science Foundation of China [82073311]
- National Key Research and Development Program of China [2020YFC2005500]
- Key Research and Development Program of Science and Technology Department of Sichuan Province [2019YFS0514]
- Applied basic research program of Science and Technology Department of Sichuan Province [2019YJ0576]
Ask authors/readers for more resources
Multiple myeloma is currently incurable, and scientists are working on developing drugs with higher specificity to improve treatment outcomes.
Multiple myeloma is currently incurable, and the incidence rate is increasing year by year worldwide. Although in recent years the combined treatment plan based on proteasome inhibitors and immuno-modulatory drugs has greatly improved the treatment effect of multiple myeloma, most patients still relapse and become resistant to current treatments. To solve this problem, scientists are committed to developing drugs with higher specificity, such as iberdomide, which is highly specific to ikaros and aiolos. This review aims to focus on the small molecular agents that are being researched/clinically used for the treatment of multiple myeloma, including the target mechanism, structure-activity relationship and application prospects of small molecular agents. (c) 2021 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
